Life-threatening pericardial bleed complicating atrial fibrillation ablation associated with Edoxaban therapy successfully managed with prothrombin complex concentrate: Edoxaban related bleed and prothrombin complex concentrate
HeartRhythm Case Reports(2020)
摘要
The risk of pericardial bleeding complicating atrial fibrillation (AF) ablation is estimated to be around 0.5%–1%.1 The consequences may be exacerbated by the need for anticoagulation for prophylaxis of thromboembolism. Once-daily administered direct oral anticoagulants (DOACs) such as edoxaban can be safely continued uninterrupted at the time of AF ablation.2 However, management of bleeding complications in the context of DOAC therapy remains a challenge, especially as anti-factor Xa DOACs do not currently have licensed specific reversal agents.
更多查看译文
关键词
Atrial fibrillation ablation,Bleeding complications,Direct oral anticoagulants,Edoxaban,Prothrombin complex concentrate
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要